Search results: (10000)
News Long-term Benefit of Luspatercept Therapy – Fresh Data from the MEDALIST Study
The goal of therapy for low-risk myelodysplastic syndrome (MDS) is to compensate for anemia, improve or maintain quality of life, and prolong the time to progression to higher-risk MDS (HR-MDS) or acute myeloid leukemia (AML). To manage anemia, we can resort to transfusion therapy or administer epoetins, lenalidomide, or luspatercept, the first representative of a class of drugs that support erythrocyte maturation. Last year's data from the follow-up of patients enrolled in the MEDALIST study pertain specifically to the latter.
News Inosine Pranobex in the Treatment of Cervical HPV Infections
The aim of the review article published in the journal Infection and Drug Resistance was to evaluate the available data on the potential use of inosine pranobex in the treatment of patients with a positive human papillomavirus finding in a cervical smear.
News Incidence of Brain Metastases and Intracranial Activity of Sotorasib in Patients with NSCLC with G12C Mutation of the KRAS Oncogene
Sotorasib is the first targeted drug approved for the treatment of metastatic non-small cell lung cancer (NSCLC) with the G12C mutation of the KRAS oncogene. The newly published study presented below investigated its intracranial activity.
News Innovation in Wound Healing: Zetuvit Plus Silicone Border for Optimal Wound Exudate Management
Excessive wound exudate can lead to delayed healing, skin damage around the wound, or leakage under the chosen dressing. Zetuvit Plus Silicone Border dressing with high absorbent and retention capacity offers confidence in treating both chronic and acute wounds and high comfort for the patient.
News AI Searches for New Antibiotics in Animal Venoms
The development of new antibiotics has stagnated for several decades for a variety of reasons. However, the use of AI could accelerate and reduce the cost of this process. Thanks to artificial intelligence, scientists are already discovering potential antibiotic sources in animal venoms.
News When to Switch to Second-Line Treatment for Primary Biliary Cholangitis?
In patients with primary biliary cholangitis (PBC), the response to ursodeoxycholic acid (UDCA) treatment is an important prognostic indicator. To identify patients with an insufficient response to this modality who require second-line therapy, the best practice is to assess the biochemical response to UDCA after 12 months of treatment. A validated and easy-to-use tool is the determination of serum alkaline phosphatase (ALP) activity and serum total bilirubin concentration. Although treatment response to UDCA is commonly checked after 12 months, a 6-month check has the same discriminatory value.
News Limits of Glycated Hemoglobin and the Importance of Other Glycated Proteins
Glycated hemoglobin is a gold standard in the diagnosis and management of diabetes treatment. However, its disadvantages include numerous factors that can cause false increases or decreases in its levels. Therefore, the scientific community is also interested in researching other glycated proteins that could be used in diabetes control. So, what should we keep in mind when collecting glycated hemoglobin?
News Correlation of Levothyroxine Dose with Autoimmune Antibody Titer in Primary Hypothyroidism
The relationship between the level of antithyroid antibodies and the required dose of levothyroxine in substitution for autoimmune hypothyroidism is a poorly explored question. Therefore, a retrospective study of more than 300 patients was conducted, and we bring you a brief summary.
News Use of Tiapride in the Treatment of Behavioral Disorders in Geriatric Patients
Hand in hand with the increasing number of people reaching an older age, there is also a rise in the occurrence of dementia. It affects the lives of patients and their families in many ways. A significant problem can be behavioral disorder, which needs to be treated adequately and promptly to prevent issues such as injuries.
News Efficacy of Ceftazidime/Avibactam in the Treatment of Infections Caused by Carbapenemase-Producing Enterobacteria
Infections caused by carbapenemase-producing enterobacteria are associated with high mortality, and their incidence continues to rise. The study presented below investigated the efficacy of therapy with the combination of ceftazidime/avibactam (a third-generation cephalosporin and a beta-lactamase inhibitor) in treating these infections compared to the 'best available antibiotic therapy' (BAT).
News MUDr. Marek Štefan: Cooperation With Pharmacists Is Essential in Antibiotic Therapy
In September, the Congress of Clinical Microbiology, Infectious Diseases and Epidemiology (KMINE) took place in Hradec Králové. What insights did it bring regarding current and emerging antibiotic therapy? And how might the discussed conclusions translate into everyday antibiotic prescribing? MUDr. Marek Štefan, MBA, from the Department of Infectious Diseases and Travel Medicine, 2nd Faculty of Medicine, Charles University, and Motol University Hospital in Prague, shared his observations on these topics.